We are pleased to announce that patient enrollment is complete in the Phase 1 portion of our ST316 Phase 1-2 clinical study! Recruitment of the Phase 2 expansion portion will begin in the coming weeks. ST316 selectively targets the WNT/β-catenin signaling pathway in tumor cells but not in normal cells, reducing the toxicity related to inhibition of this pathway. The WNT/β-catenin signaling pathway is one of the most active pathways in several cancers and drives more than 80% of colorectal cancers – the first indication to be assessed in Phase 2. We are incredibly proud of the execution by our clinical team in achieving this milestone according to planned timelines. We send heartfelt thanks for the contribution of all participants in this study and the support of our clinical collaborators at each site. #Colorectalcancer #ClinicalTrials #Oncology #DrugDevelopment
Great news! Congrats!
Congrats Marisa Frackman and team!
Great news!
Congratulations Nancy! Great milestone!
Congratulations to our team! Moving forward...